International Journal of Clinical Science and Medical Research

Setting: Intrepid Nepal Pvt Ltd, Thapathali, Kathmandu, Nepal between August 2020 and August 2023

Objectives: To determine the prevalence of Human papillomavirus and their type specific distribution among women 

Design: laboratory based, cross sectional study

Results: Among the 6474 samples received, 574 were identified as Human papillomavirus. Overall, the prevalence of the HPV isolates were found to be 9.4%.

Genotyping of 51 women sample were done. All infection with High-risk type. 66.6% single infection and 33.3% multiple infection. Most common HR HPV were HPV 16(33.3%), followed by HPV 56(17.6%), 66(15.6), 18(13.7%), 58(13.7%), 59(11.7%), 31(7.8%), 39(7.8%), 51(5.8), 52(5.8%), 68(5.8%). Higher HPV prevalence among young adult (20-39 years), followed by middle age adult and senior adult.

Conclusion: Our results highlight the current status of HPV prevalence and genotypes among women in Nepal. The highest prevalence was found among 20-30 years. HPV vaccine is strongly recommended for regular immunization before the onset of sexual activities 9-13 years to reduce the burden of cervical cancer. 

Human papillomavirus, Genotyping, Prevalence, Nepali women

1. Crosbie EJ, Einstein MH, Franceschi S and Kitchener HC: Human papillomavirus and cervical cancer. Lancet 382(9895): 889-899, 2013.
2. De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. 
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:71:209–49. doi:10.3322/caac.21660. 
4. World Health Organization. Human Papillomavirus(HPV) and cervical cancer. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer. Accessed 22 Feb, 2022
5. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
6. GLOBOCAN 2020. Global Cancer Observatory: Cancer Today [Internet]. Lyon, France: International Agency for Research on Cancer; 2020 [cited 2021 December 17]. Available from: https://gco.iarc.fr/today
7. Shrestha AD, Andersen JG, Gyawali B, Shrestha A, Shrestha S, Neupane D, et al. Cervical cancer screening utilization, and associated factors, in Nepal: a systematic review and meta-analysis. Public Health. (2022) 210:16– 25. doi: 10.1016/j.puhe.2022.06.007 
8. Family Health Division. National guidelines for cervical cancer screening and prevention in Nepal. In: Department of Health Services, Ministry of Health and Population, editor. Kathmandu: Family Health Division; 2010. 
9. Family Health Services. Cervical cancer screening and prevention in Nepal implementation plan 2016-2020. In: Department of Health Services, Ministry of Health and Population, editor. Teku, Kathmandu: Family Health Services; 2017. 
10. Dhimal M, Bista B, Bhattarai S, Dixit LP, Hyder MKA, Agrawal N, et al. Report of non communicable disease risk factors: STEPS survey Nepal 2019. Kathmandu: Nepal Health Research Council; 2020. https://www.who.int/docs/default-source/nepal-documents/ncds/ncd-steps-survey-2019 
11. Zeng, H., Chen, W., Zheng, R., Zhang, S., Ji, J. S., Zou, X., et al. (2018). Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob. Health 6, e555–e567. doi: 10.1016/ S2214-109X(18)30127-X 
12. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518–527. 
13. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012; 100B: 1–441.
14. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, et al. Preventable exposures associated with human cancers. JNCI J Natl Cancer Inst. 2011;103:1827–39.
15. Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M. Pathogenic role of the eight probably/ possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervi- cal cancer. J Pathol. 2014;234(4):441–51. 
16. Gultekin M, Ramirez PT, Broutet N, Hutubessy R. World Health Organiza- tion call for action to eliminate cervical cancer globally. Int J Gynecol Cancer. 2020;30:426-7
17. G. Ronco, N. Segnan, P. Giorgi-Rossi et al., “Human papillo- mavirus testing and liquid-based cytology: results at recruit- ment from the new technologies for cervical cancer randomized controlled trial,” Journal of the National Cancer Institute, vol. 98, no. 11, pp. 765–774, 2006. 
18. WHO, WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, WHO Guide- lines Approved by the Guidelines Review Committee, Geneva, 2nd edition, 2021. 
19. Johnson D, Bhatta MP, Smith JS, Kempf MC, Broker TR, Vermund SH, et al. Assessment of high-risk human papillomavirus infections using clinician- and self-collected cervical sampling methods in rural women from Far Western Nepal. PLoS One. 2014;9(6):e101255. 
20. Khoo SP, Bhoo-Pathy N, Yap SH, et al (2018). Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV) carriage in a cross-sectional, multiethnic, community-based female Asian population. Sex Transm Infect, 94, 277-83
21. Srivastava S, Gupta S, Roy JK. High prevalence of oncogenic HPV-16 in cervical smears of asymptomatic women of eastern Uttar Pradesh, India: a population-based study. J Biosci. 2012;37:63–72. 
22. Sherpa AT, Clifford GM, Vaccarella S, Shrestha S, Nygard M, Karki BS, et al. Human papillomavirus infection in women with and without cervical cancer in Nepal. Cancer Causes Control. 2010;21:323–30.
23. Bhatta, M.P., Johnson, D.C., Lama, M. et al. High-risk human papillomavirus infection and abnormal cervical cytology among Nepali and Bhutanese refugee women living in eastern Nepal. BMC Infect Dis 17, 73 (2017). https://doi.org/10.1186/s12879-017-2186-2
24. Shakya S, Syversen U, Åsvold BO, Bofin AM, Aune G, Nordbo SA, et al. Prevalence of human papillomavirus infection among women in rural Nepal. Acta Obstet Gynecol Scand 2017;96:29–38.DOI: 10.1111/aogs.13036 
25. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl 10):K1–K16.
26. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ: Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age- related patterns for high-risk and low-risk types. Int J Cancer 2000, 87:221–227. 
27. Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de la Campa A: Asian- American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001, 93:1325–1330. 
28. Rolon PA, Smith JS, Munoz N, Klug SJ, Herrero R, Bosch X, Llamosas F, Meijer CJ, Walboomers JM: Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 2000, 85:486–491. 
29. Wang, X., Song, Y., Wei, X. et al. Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China. Virol J 19, 6 (2022). https://doi.org/10.1186/s12985-021-01732-8
30. Bruno MT, Scalia G, Cassaro N, Boemi S. Multiple HPV16 infection with two strains: a possible marker of neoplastic progression. BMC Cancer. 2020;20(1):444. 
31. Thapa N, Maharjan M , Shrestha G, et al. Prevalence and type-specific distribution of human papillomavirus infection among women in mid-western rural, Nepal- A population-based study. BMC Infec Diseas 18:338 (2018) https://doi.org/10.1186/s12879-018-3175-9 
32. Sanjosé S, Díaz M, Castellsagué X, Clifford G, Bruni L. Worldwide prevalence and genotype distribution of cervical HPV in women with normal cytology. Lancet Infect. 2007;7:453–9. Available from:https://www.thelancet.com/ journals/laninf/article/PIIS1473-3099(07)70158-5/fulltext. 
33. Bao Y-P, Li N, Smith JS, Qiao Y-L, ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008;18:71–79.
34. Hamlin-Douglas LK, Coutlée F, Roger M, Franco EL, Brassard P. Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomark Prev. 2008;17: 3141–9.
35. Franceschi S, Rajkumar R, Snijders P, Arslan A, Mahe C, Plummer M, et al. Papillomavirus infection in rural women in southern India. Br J Cancer. 2005;92:601–6
36. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PTH, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677–84.
37. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004;57(1):68–72. doi: 10.1136/jcp.57.1.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL: Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomark Prev 2006, 15:1274–1280. 
39. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco MD, Silini EM: Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol 2009, 113:115–119.
40. Department of Health Services, Ministry of Health & Population (2010) National Guideline for Cervical Cancer Screening and Prevention in Nepal. http://whonepal.healthrepository.org/bitstream/123456789/498/1/National%20Guideline%20for%20CCSP.pdf.